


(Protein Kinases)

VS

Protein Phosphatases

- ancient enzymes essential to cell signaling and cellular regulation*
- new targets for Pharmaceuticals*




Protein Phosphatases (PPPs)
are highly conserved
through evolution among
of all enzymes...

Proteins **unit of evolution**
(millions of yrs for 1% change)

Histone H4	400
Calmodulin	350
Histone H3	330
PP-2A α	100
PP-1 α	88
PP-2 β	66
Histone H-2A, H-2B	60
GDH	55
Tubulin	40
PKA	39
Collagen	36
G α i	32
K ⁺ channel	22


From H.C.-Li 2001

PPPs of all three families are present from yeast to plants and mammals.
And in many cases, also in prokaryotes (bacteria and archaeobacteria).



Protein Phosphorylation

rapid and reversible biochemical reactions



A molecular on/off switching mechanism

“Writer & Eraser”

Protein Phosphorylation: Kinases & Phosphatases

Protein phosphorylation: Kinases & phosphatases

Protein Tyr kinases

Protein Ser/Thr kinases

ATP

KINASE superfamily
~ 500 enzymes
90 PTK > 400 PSK

ATP

Substrate → Substrate-Tyr-P

Substrate → Substrate-Ser/Thr-P

Cys-SH

PTP

Protein Tyr(P) phosphatases

Dual-specificity phosphatases

DUSP

PIP phosphatases (PTEN)

PPP

Fe::Zn

Mn-Mg

PPM1

Asp phosphatases

DxDxT


Protein Ser(P)/Thr(P) phosphatases

~90
PTP


~90 PPP

Protein Ser/Thr Phosphatases
Phosphoprotein phosphatases
(PPP family)

Three families of Ser/Thr Protein Phosphatases




The PPP Family of Protein Ser/Thr Phosphatases



Toxin-sensitive PPP

PP1

PP2A
PP4
PP6



CaN (PP2B)

PP5

Red = human
Green = Drosophila
Yellow = yeast

Inhibiting PPPs

PP-1 and PP-2A are inhibited by **okadaic acid** (shellfish toxin) and **microcystin** (cyclic peptides produced by cyanobacteria which are potent hepatotoxins).


Also PP-4, PP-5 and PP-6 are inhibited, while PP-2B is inhibited by higher (mM) concentrations.

PP-2B is a target of **cyclosporin A** and **FK506** (immunosuppressants)

Cyclosporin A (CsA) is a lipid soluble fungal undecapeptide ($M_r=1,203$) widely used in transplantation for graft rejection; functions as blocker of T cell activation or proliferation. CsA binds cyclophilin (CyPA) and this complex binds B subunit of calcineurin in presence of calcium/calmodulin to inhibit PP activity.

FK506 is a bacterial (Streptomyces) product, a macrocyclic lactone structurally unrelated to cyclophilin that complexes with FKB binding protein (FKBP12 from the TGF- β receptors signaling) to inhibit calcineurin PP activity.


Natural Toxins from Diverse Sources Bind and Inhibit PPP Protein Phosphatases




Motuporin [Nodularin-V]

Microcystin-LR

Blue-green Algae




Okadaic acid




Calyculin A

Dinoflagellates
Prorocentrum lima


Blister beetle *Coleoptera*



Cantharidin



Norcantharidin




Fostriecin

Streptomyces (fostreus)

Protein Ser/Thr Phosphatases Are Dominant over Protein Kinases



*(most proteins are **maintained** in a dephosphorylated state!)*



Cell Signaling Technology 2002 catalogue (pg. 15): Western blot analysis of whole cell lysates of Jurkat cells, untreated with 0.1 μ M calyculin A for 20 minutes prior to lysis, using Phospho-Thr antibody.

Catalytic Subunit of Protein Phosphatase-1 (PP1)


PP1, the most widely expressed protein Ser/Thr phosphatase that is responsible for more than 50% of all dephosphorylation reactions in humans...




Okadaic Acid Binds at the Active Site of PPP Protein Phosphatases

Mechanism of Phospho-Ester Hydrolysis by PPP Phosphatases:

in-line attack of metal-activated hydroxide, with trigonal bipyramid intermediate and inversion of stereochemistry protonation of the leaving alcoholic group by the His of the active site.



PPP/PPM Family Mechanism




Type-1 Protein Phosphatase (PP1)

1. Bi-metallic active site with Fe and Zn
2. 3D structure - beta sheet and alpha helix clusters
3. Isoforms α , γ_1 , γ_2 , δ
differences mostly in C terminal, allow specific antibodies

alpha	NPGGRPITPPRN--SAKAKK
gamma	--ATRPVTPPRGMITKQAKK
delta	NSG-RPVTPPRTANPPK-KR
4. > 200 regulatory subunits
5. Toxins - microcystin, okadaic acid, calyculin A bind at active site
(3D structures)

Protein Ser(P)/Thr(P) Phosphatase - PP1

many different regulatory-targeting subunits
complex with common catalytic subunit




Type-2A Protein phosphatase (PP2A)

Catalytic subunit

1. Bimetal center Fe::Zn and catalytic mechanism same as PP1
2. 3D structure...known in complex with A and in ABC
3. Isoforms α , β 10:1 ratio, essential for development
4. **DYFL**_{COOH} motif at C terminus conserved
phosphorylation - PTKs, eg. Src, JAK
methylation - PMT and PME, alters subunit association
5. Toxins – MCLR and OA bind at active site.
Differences between PP1 and PP2A in β 12- β 13 loop
=>differences in inhibitory doses

Protein phosphatase 2A describes a panoply of phosphatases




The common heterotrimeric form of PP2A contains a pair of the catalytic subunit (C), the structural A/PR65 subunit and a regulatory/targeting B subunit (at least 15 distinct B subunits are known).

Various cellular and viral proteins interact with PP2A components as indicated...

Virshup, DM (2000) Current Opinion in Cell Biol 12:180-185

PP2A can be > 80 different “enzymes”

The Structural Basis of Substrate Recognition by PP2A



PP2C= Mn^{2+}/Mg^{2+} -dependent PPase (PPM)

A. Catalytic subunit

1. unrelated to PPP but bimetallic Mg:Mn active center
2. isoforms α , β_1 , β_2 , etc.
3. many new family members in plants genome

B. Regulatory subunits - none?

C. Inhibitor Proteins - none?


D. Substrates

1. CDKs
 2. the kinase activation loop
 3. PI3K
 4. Glycogen synthase
- ...others

Human Protein Phosphatase 2C Metal (Mn^{2+})-dependent Phosphatase (MPP)



Abscisic Acid–Mediated Plant Stress Responses






Protein Tyrosine Phosphatases (PTPs)

PTP(-like) Phosphatases in The Human Genome (107 genes): ~90 active enzymes


transmembrane

cytoplasmic

assorted others



Crystal structures of six PTP domains show a conserved fold and C α -backbone



Superimposition of PTP1B (magenta), RPTP α (gray), RPTP μ (red), LAR (blue), SHP1 (green) and SHP2 (yellow).

The PTP1B active site





Figure 4 Structure of protein tyrosine phosphatase 1B. The PTP loop (dark shading) and WPD loop are indicated, as is Cys 215 and Arg 221 of the PTP loop and the position of the C α -atom of Tyr 46 of the phosphotyrosine recognition loop.

The PTP1B active site



Sub-Families of Tyr Phosphatases (PTPs)

1. Transmembrane PTPs - *the prototype CD-45*

a. common features (most)


1. single TM helix to span membrane
2. double PTP domain, with activity in N terminal (D1) domain
3. large extracellular domains, related to cell-cell adhesion
4. inhibited by dimerization? Oxidation?
5. activators of src kinases by Tyr527 dephosphorylation

b. differences


1. tissue and developmental expression
2. substrate specificity, but few targets known knockouts and trapping mutants
3. inhibitors of active sites as pharmaceuticals

Receptor-like PTPs

Transmembrane Proteins



Differential expression




E14-16

LAR


PTP-sigma

PTP-delta




Receptor PTPs catalytic activity is regulated by dimerization:

-Monomeric RTKs exhibit weak basal activity. Ligand binding of RTKs leads to dimerization, trans-autophosphorylation, and activation.



Receptor PTPs catalytic activity is regulated by dimerization:

-Monomeric RPTPs exhibit enhanced catalytic activity. Ligand binding of RPTPs leads to dimerization of membrane-proximal PTP domains. 'Inhibitory wedge' sequences from each phosphatase domain interact with the other catalytic domain, preventing substrate binding.



2. Cytosolic PTPs, *the prototype PTP1B*


a. common features

1. single PTP domain, plus targeting sequences
2. specificity for P-Tyr vs P-Ser
3. Phospho-Cys-enzyme intermediate
4. Substrate trap by conformational movement
5. Oxidation-reduction control mechanism

b. differences

1. tissue expression
2. specificity for substrates
3. Inhibition by small molecules

InsR Signaling



Resistance to High Fat Diet




Fig. 5. Resistance of PTP-1B null and heterozygous mice to diet-induced obesity.

Tyrosine Phosphorylation of Insulin Receptor






Fig. 4. Increased and prolonged tyrosine phosphorylation of the insulin receptor in PTP-1B^{-/-} mice. (A) ...

Muscle

Muscle

Co-Crystal of PTP1B with Chemical Inhibitor - Cmpd2




Compound 2, $K_i = 1.8$ nM

3. Dual Specificity Phosphatases, *the prototype VH1*

- a. mechanism common with PTPs, i.e. Cys-based catalytic site,
which is shallow enough to accommodate p-Ser/p-Thr substrates
- b. the MKPs (DUSPs), **MAP kinase phosphatases**
binds to MAPK at site using N-terminal domain through CH2
motif, and this activates the MKP terminal catalytic domain
several members : CL100, MKP1, 2, 3, 5, 7
- c. the Cdc25 family of **CDK phosphatases**
low activity phosphatase with extreme specificity
large inhibitory domain, activated by phosphorylation
not really a family member- it's like Rhodanese (Thiosulphate
transferase: converts CN⁻ in SCN⁻)

The Dual Specificity Phosphatases




Dual-Specificity Phosphatase: DUSPs



MAPK Phosphatase: Catalytic domain reacts with pTyr-X-pThr

MKP signature sequence is **HCXXXXXR**:

- Nucleophilic attack of cysteine thiolate anion on MAPK P-Tyr
- Aspartate in acid loop donates proton
- Arginine coordinates phosphate group of P-Tyr or P-Thr
- Histidine decreases pKa of cysteine so it exists as anion



MAPK Phosphatases : Use of Docking + Catalysis



PTP Inhibitors

PTP Inhibitor Design (e.g. vs. PTP1B for diabetes and Cdc25 for cancer)

pTyr alone insufficient for high affinity binding to PTPs--adjacent residues contribute to specificity


By analogy, kinase inhibitor specificity determined by binding to region outside ATP binding pocket--for PTPase, pTyr binding domain is smaller than kinase ATP pocket (pTyr takes up ~50% of binding pocket)

So small molecule inhibitors:

--Need to bind PTP catalytic domain and another adjacent region unique to a specific PTP simultaneously to confer specificity (based on structure PTP1B and inh. BPPM)

--Need to penetrate cell membranes

A strategy for creating selective and high-affinity PTP1B inhibitors. Based on the principle of additivity of free energy of binding, high-affinity ligands can be obtained by linking two functional groups that bind to the active site (pTyr binding site) and a peripheral site X. Specificity arises from the fact that site X is not conserved and from the fact that the tethered ligand has to bind both sites simultaneously. Zhang ZY (2002) Annu Rev Pharmacol Toxicol. 42:209-34





Fabio Luis Forti



E-mail: fiforti@iq.usp.br

Função: Professor Associado

Departamento: Departamento de Bioquímica

Telefone Direto: 3091-9905

Telefone do Laboratório: 3091-2172

Bloco: 9i


Sala: 924

Tema da Pesquisa: Rho GTPases e Tirosina Fosfatases: Funções Celulares e Moleculares

Laboratório de Sinalização em
Sistemas Biomoleculares (LSSB)

<http://www2.iq.usp.br/docente/flforti/>

Cdc25 - not really related to other PTPs



Cell cycle. CDK1 (CDC2 or p34cdc2) is inactive in G1 due to phosphorylation on Thr14, Tyr15 and Thr161. Critical threshold concentration of CDK1 at G2/M transition results in increased dephosphorylation of Thr14, Tyr15 by **Cdc25**, a dual specificity phosphatase, leading to CDK1 activation.